As researchers intensify their quest to understand cancer progression, the spotlight has unexpectedly turned toward a surprising villain: senescent macrophages. These paradoxical cells, originally hailed as immune defenders, are now under scrutiny for their complicity in fueling tumor growth. The
In a bold maneuver to realign its strategic focus, Belgian pharmaceutical firm Galapagos is contemplating the sale of its cell therapy unit, a move that represents a significant departure from its initial restructuring plan. Originally, this unit was poised to become the cornerstone of a strategic
In the ever-evolving landscape of cancer therapies, one of the most significant breakthroughs has been the use of monoclonal antibodies and immune checkpoint inhibitors (ICIs). These therapies aim to enhance the immune system's ability to recognize and eliminate tumors. However, the effectiveness
The field of cancer treatment is witnessing seismic shifts as MiNK Therapeutics, a clinical-stage biotechnology firm and subsidiary of Agenus Inc., introduces groundbreaking cell-based therapies focused on treating challenging cancers. With its pioneering work on invariant natural killer T (iNKT)
The Centers for Medicare & Medicaid Services (CMS) has taken a significant step in healthcare innovation by unveiling a pioneering model designed to improve access to advanced treatments for Medicaid patients affected by sickle cell disease. This initiative, focused on the Cell and Gene Therapy
In recent years, innovative developments in medical research have led to significant strides in addressing rare genetic disorders like cystic fibrosis (CF). One remarkable advancement is the introduction of Alyftrek, a triple combination therapy approved by the National Institute for Health and
